Literature DB >> 22504207

Auditory steady state responses in a schizophrenia rat model probed by excitatory/inhibitory receptor manipulation.

Jenifer L Vohs1, R Andrew Chambers, Brian F O'Donnell, Giri P Krishnan, Sandra L Morzorati.   

Abstract

Alterations in neural synchrony and oscillations may contribute to the pathophysiology of schizophrenia and reflect aberrations in cortical glutamatergic and GABAergic neurotransmission. We tested the effects of a GABA agonist and an NMDA antagonist on auditory steady state responses (ASSRs) in awake rats with neonatal ventral hippocampal lesions (NVHLs) as a neurodevelopmental model of schizophrenia. NVHL vs. SHAM lesioned rats were injected with saline then either ketamine (NMDA antagonist) or muscimol (GABA(A) agonist). Time-frequency analyses examined alterations in phase locking (consistency) across trials and changes in total power (magnitude). ASSRs were compared at five stimulation frequencies (10, 20, 30, 40, and 50 Hz). In SHAM rats, phase locking and power generally increased with stimulation frequency. Both ketamine and muscimol also increased phase locking and power in SHAM rats, but mostly in the 20 to 40 Hz range. NVHL and ketamine altered the frequency dependence of phase locking, while only ketamine changed power frequency dependence. Muscimol affected power, but not phase locking, in the NVHL rats. NVHL and ketamine models of schizophrenia produce similar independent effects on ASSR, potentially representing similar forms of cortical network/glutamatergic dysfunction, albeit the effects of ketamine were more robust. Muscimol produced NVHL-dependent reductions in ASSR measures, suggesting that cortical networks in this model are intolerant to post-synaptic GABAergic stimulation. These findings suggest the utility of combining lesion, pharmacological, and ASSR approaches in understanding neural mechanisms underlying disturbed synchrony in schizophrenia.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22504207      PMCID: PMC3443327          DOI: 10.1016/j.ijpsycho.2012.04.002

Source DB:  PubMed          Journal:  Int J Psychophysiol        ISSN: 0167-8760            Impact factor:   2.997


  50 in total

Review 1.  Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence.

Authors:  A Carlsson; N Waters; S Holm-Waters; J Tedroff; M Nilsson; M L Carlsson
Journal:  Annu Rev Pharmacol Toxicol       Date:  2001       Impact factor: 13.820

Review 2.  Multiple origins of the cortical γ rhythm.

Authors:  Miles A Whittington; Mark O Cunningham; Fiona E N LeBeau; Claudia Racca; Roger D Traub
Journal:  Dev Neurobiol       Date:  2011-01-01       Impact factor: 3.964

3.  Exaggerated MK-801-induced motor hyperactivity in rats with the neonatal lesion of the ventral hippocampus.

Authors:  H A Al-Amin; D R Weinberger; B K Lipska
Journal:  Behav Pharmacol       Date:  2000-06       Impact factor: 2.293

Review 4.  A roadmap for the development and validation of event-related potential biomarkers in schizophrenia research.

Authors:  Steven J Luck; Daniel H Mathalon; Brian F O'Donnell; Matti S Hämäläinen; Kevin M Spencer; Daniel C Javitt; Peter J Uhlhaas
Journal:  Biol Psychiatry       Date:  2010-12-15       Impact factor: 13.382

5.  Gamma frequency-range abnormalities to auditory stimulation in schizophrenia.

Authors:  J S Kwon; B F O'Donnell; G V Wallenstein; R W Greene; Y Hirayasu; P G Nestor; M E Hasselmo; G F Potts; M E Shenton; R W McCarley
Journal:  Arch Gen Psychiatry       Date:  1999-11

6.  Cortical-striatal integration of cocaine history and prefrontal dysfunction in animal modeling of dual diagnosis.

Authors:  R Andrew Chambers; Alena M Sentir; Susan K Conroy; William A Truitt; Anantha Shekhar
Journal:  Biol Psychiatry       Date:  2009-10-31       Impact factor: 13.382

7.  GABAergic modulation of the 40 Hz auditory steady-state response in a rat model of schizophrenia.

Authors:  Jenifer L Vohs; R Andrew Chambers; Giri P Krishnan; Brian F O'Donnell; Sarah Berg; Sandra L Morzorati
Journal:  Int J Neuropsychopharmacol       Date:  2009-07-23       Impact factor: 5.176

8.  Acoustic hypersensitivity in adult rats after neonatal ventral hippocampus lesions.

Authors:  Carlos Eduardo Macedo; Marie-Josée Angst; Thierry Guiberteau; David Brasse; Terence John O'Brien; Guy Sandner
Journal:  Behav Brain Res       Date:  2009-10-08       Impact factor: 3.332

9.  Ketamine modulates theta and gamma oscillations.

Authors:  Maciej T Lazarewicz; Richard S Ehrlichman; Christina R Maxwell; Michael J Gandal; Leif H Finkel; Steven J Siegel
Journal:  J Cogn Neurosci       Date:  2010-07       Impact factor: 3.225

Review 10.  Steady state responses: electrophysiological assessment of sensory function in schizophrenia.

Authors:  Colleen A Brenner; Giri P Krishnan; Jenifer L Vohs; Woo-Young Ahn; William P Hetrick; Sandra L Morzorati; Brian F O'Donnell
Journal:  Schizophr Bull       Date:  2009-09-02       Impact factor: 9.306

View more
  21 in total

1.  Gender and modulation frequency effects on auditory steady state response (ASSR) thresholds.

Authors:  Mohd Normani Zakaria; Bahram Jalaei; Nor Alaudin Abdul Wahab
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-02-15       Impact factor: 2.503

Review 2.  Impact of ketamine on neuronal network dynamics: translational modeling of schizophrenia-relevant deficits.

Authors:  Bernat Kocsis; Ritchie E Brown; Robert W McCarley; Mihaly Hajos
Journal:  CNS Neurosci Ther       Date:  2013-04-24       Impact factor: 5.243

3.  Stimulus train duration but not attention moderates γ-band entrainment abnormalities in schizophrenia.

Authors:  Jordan P Hamm; Anastasia M Bobilev; Lauren K Hayrynen; Matthew E Hudgens-Haney; William T Oliver; David A Parker; Jennifer E McDowell; Peter A Buckley; Brett A Clementz
Journal:  Schizophr Res       Date:  2015-04-11       Impact factor: 4.939

4.  MEG and EEG demonstrate similar test-retest reliability of the 40Hz auditory steady-state response.

Authors:  Kristina T Legget; Allison K Hild; Sarah E Steinmetz; Steven T Simon; Donald C Rojas
Journal:  Int J Psychophysiol       Date:  2017-02-01       Impact factor: 2.997

5.  Sensory encoding in Neuregulin 1 mutants.

Authors:  Claudia S Barz; Thomas Bessaih; Ted Abel; Dirk Feldmeyer; Diego Contreras
Journal:  Brain Struct Funct       Date:  2014-12-17       Impact factor: 3.270

6.  Psilocybin-Mediated Attenuation of Gamma Band Auditory Steady-State Responses (ASSR) Is Driven by the Intensity of Cognitive and Emotional Domains of Psychedelic Experience.

Authors:  Vojtěch Viktorin; Inga Griškova-Bulanova; Aleksandras Voicikas; Dominika Dojčánová; Peter Zach; Anna Bravermanová; Veronika Andrashko; Filip Tylš; Jakub Korčák; Michaela Viktorinová; Vlastimil Koudelka; Kateřina Hájková; Martin Kuchař; Jiří Horáček; Martin Brunovský; Tomáš Páleníček
Journal:  J Pers Med       Date:  2022-06-19

Review 7.  Auditory dysfunction in schizophrenia: integrating clinical and basic features.

Authors:  Daniel C Javitt; Robert A Sweet
Journal:  Nat Rev Neurosci       Date:  2015-09       Impact factor: 34.870

8.  40 Hz Auditory Steady-State Response Is a Pharmacodynamic Biomarker for Cortical NMDA Receptors.

Authors:  Digavalli V Sivarao; Ping Chen; Arun Senapati; Yili Yang; Alda Fernandes; Yulia Benitex; Valerie Whiterock; Yu-Wen Li; Michael K Ahlijanian
Journal:  Neuropsychopharmacology       Date:  2016-02-03       Impact factor: 7.853

9.  Effects of NMDA and GABA-A Receptor Antagonism on Auditory Steady-State Synchronization in Awake Behaving Rats.

Authors:  Elyse M Sullivan; Patricia Timi; L Elliot Hong; Patricio O'Donnell
Journal:  Int J Neuropsychopharmacol       Date:  2015-01-02       Impact factor: 5.176

Review 10.  A roadmap for development of neuro-oscillations as translational biomarkers for treatment development in neuropsychopharmacology.

Authors:  Daniel C Javitt; Steven J Siegel; Kevin M Spencer; Daniel H Mathalon; L Elliot Hong; Antigona Martinez; Cindy L Ehlers; Atheir I Abbas; Tobias Teichert; Peter Lakatos; Thilo Womelsdorf
Journal:  Neuropsychopharmacology       Date:  2020-05-06       Impact factor: 8.294

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.